DK3204400T3 - 17alfa,21-diestere af cortexolon til anvendelse i behandling af tumorer - Google Patents
17alfa,21-diestere af cortexolon til anvendelse i behandling af tumorer Download PDFInfo
- Publication number
- DK3204400T3 DK3204400T3 DK15778634.4T DK15778634T DK3204400T3 DK 3204400 T3 DK3204400 T3 DK 3204400T3 DK 15778634 T DK15778634 T DK 15778634T DK 3204400 T3 DK3204400 T3 DK 3204400T3
- Authority
- DK
- Denmark
- Prior art keywords
- carcinoma
- compound
- cortexolone
- compounds
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Claims (23)
1. Forbindelse med formlen (I):
hvor: RerC(O)-Ri; Ri er et hydrogen eller en lineær alkylkæde, der indeholder 2 til 5 carbonatomer; og R' er en lineær alkylkæde, der indeholder 3 til 6 carbonatomer eller en eventuelt substitueret arylgruppe eller en eventuelt substitueret heteroarylgruppe; hvor Ri og R' ikke er ens.
2. Forbindelse ifølge krav 1, hvor den eventuelt substituerede arylgruppe er phenyl.
3. Forbindelse ifølge krav 1, hvor Ri er hydrogen eller CH2CH3, og R' er -(CH2)3-CH3 eller phenyl.
4. Forbindelse ifølge krav 1 med formlen:
Cortexolon 17a-valerat-21 -propionat
5. Forbindelse ifølge et hvilket som helst af kravene 1 til 4 til anvendelse som et lægemiddel.
6. Forbindelsen til anvendelse ifølge krav 5 med formlen:
7. Forbindelse ifølge et hvilket som helst af kravene 1 til 4 til anvendelse i behandlingen af præcancerøse læsioner, dyspiasier, metaplasier og tumorsygdomme, der eventuelt indbefatter maligne neoplasier og metastaser.
8. Forbindelse ifølge et hvilket som helst af kravene 1 til 4 til anvendelse som et antitumormiddel.
9. Forbindelse til anvendelse ifølge krav 7 eller 8, hvor tumorsygdommene er solide tumorer, fortrinsvis epitheliale tumorer, mere fortrinsvis hvor de epitheliale tumorer er prostatakarcinom; mammakarcinom; pankreaskarcinom; lungekarcinom; karcinom i fordøjelseskanalen, såsom colonkarcinom; nyrecancer; thyroideakarcinom; uteruskarcinom eller binyrekarcinom.
10. Forbindelse til anvendelse ifølge krav 9, hvor de epitheliale tumorer er prostatakarcinom, hvor prostatakarcinomet fortrinsvis er eller bliver resistent over for anti-androgen-målrettet terapi, såsom enzalutamid; pankreaskarcinom, fortrinsvis eksokrint pankreaskarcinom; mammakarcinom, fortrinsvis triple-negativ brystcancer (TNBC), fortrinsvis hvor mammakarcinomet er triple-negativ brystcancer og individet har tilbagefald eller ikke reagerer på konventionel terapi; eller karcinom i fordøjelseskanalen, såsom colonkarcinom.
11. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 7 til 10, hvor forbindelsen er cortexolon 17a-valerat-21-propionat.
12. Forbindelse ifølge et hvilket som helst af kravene 1 til 4 til anvendelse som en glucocorticoidreceptor- (GR) modulator, fortrinsvis til anvendelse som en glucocorticoidantagonist.
13. Forbindelsen til anvendelse ifølge krav 12 med formlen:
14. Farmaceutisk sammensætning, der omfatter mindst én forbindelse ifølge et hvilket som helst af kravene 1 til 4 og mindst én fysiologisk acceptabel excipiens.
15. Farmaceutisk sammensætning ifølge krav 14, der endvidere omfatter mindst én anden aktiv bestanddel.
16. Farmaceutisk sammensætning ifølge krav 14 og mindst én anden aktiv bestanddel, fortrinsvis en kemoterapeutisk aktiv bestanddel, til simultan, separat eller sekventiel administration.
17. Farmaceutisk sammensætning ifølge et hvilket som helst af kravene 14 - 16 til anvendelse i behandlingen af præcancerøse læsioner, dyspiasier, metaplasier og tumorsygdomme, der eventuelt indbefatter maligne neoplasier og metastaser.
18. Farmaceutisk sammensætning ifølge et hvilket som helst af kravene 14 - 16 til anvendelse som et antitumormiddel.
19. Farmaceutisk sammensætning til anvendelse ifølge krav 17 eller 18, hvor tumorsygdommene er solide tumorer, fortrinsvis epitheliale tumorer, såsom prostatakarcinom; mammakarcinom; pankreaskarcinom; lungekarcinom; karcinom i fordøjelseskanalen, såsom colonkarcinom; nyrecancer; thyroideakarcinom; uteruskarcinom; binyrekarcinom.
20. Farmaceutisk sammensætning til anvendelse ifølge krav 19, hvor de epitheliale tumorer er prostatakarcinom, hvor prostatakarcinomet fortrinsvis er eller bliver resistent over for anti-androgen-målrettet terapi, såsom enzalutamid; pankreaskarcinom, fortrinsvis eksokrint pankreaskarcinom; mammakarcinom, fortrinsvis triple-negative brystcancer (TNBC), fortrinsvis hvor mammakarcinomet er triple-negativ brystcancer og individet har tilbagefald eller ikke reagerer på konventionel terapi; eller karcinom i fordøjelseskanalen, såsom colonkarcinom.
21. Farmaceutisk sammensætning ifølge et hvilket som helst af kravene 14 til 20, hvor forbindelsen er cortexolon 17 a-valerat-21-propionat.
22. Farmaceutisk sammensætning ifølge krav 14 til anvendelse som en glucocorticoidreceptor-(GR) modulator, fortrinsvis til anvendelse som en glucocorticoidantagonist.
23. Farmaceutisk sammensætning ifølge krav 22, hvor forbindelsen er cortexolon 17a-valerat-21-propionat.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14188063.3A EP3006453A1 (en) | 2014-10-08 | 2014-10-08 | 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors |
PCT/EP2015/073172 WO2016055533A1 (en) | 2014-10-08 | 2015-10-07 | 17a,21-diesters of cortexolone for use in the treatment of tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3204400T3 true DK3204400T3 (da) | 2019-03-04 |
Family
ID=51687868
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18198653.0T DK3456330T3 (da) | 2014-10-08 | 2015-10-07 | Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer |
DK15778634.4T DK3204400T3 (da) | 2014-10-08 | 2015-10-07 | 17alfa,21-diestere af cortexolon til anvendelse i behandling af tumorer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18198653.0T DK3456330T3 (da) | 2014-10-08 | 2015-10-07 | Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer |
Country Status (23)
Country | Link |
---|---|
US (7) | US10183030B2 (da) |
EP (4) | EP3006453A1 (da) |
JP (5) | JP6735739B2 (da) |
KR (4) | KR20230052990A (da) |
CN (5) | CN111285913B (da) |
AU (3) | AU2015329999B2 (da) |
BR (2) | BR112017007078A2 (da) |
CA (3) | CA3160391A1 (da) |
DK (2) | DK3456330T3 (da) |
ES (3) | ES2713699T3 (da) |
HR (2) | HRP20190194T1 (da) |
HU (2) | HUE041503T2 (da) |
IL (3) | IL272095B2 (da) |
LT (2) | LT3456330T (da) |
MX (3) | MX366294B (da) |
PL (2) | PL3204400T3 (da) |
PT (2) | PT3204400T (da) |
RS (2) | RS62147B1 (da) |
RU (2) | RU2712752C2 (da) |
SI (2) | SI3204400T1 (da) |
TR (1) | TR201901422T4 (da) |
WO (2) | WO2016055537A1 (da) |
ZA (2) | ZA201702209B (da) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
EP3006453A1 (en) | 2014-10-08 | 2016-04-13 | Cosmo Technologies Ltd. | 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors |
US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
KR102342620B1 (ko) | 2017-03-31 | 2021-12-22 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 자궁경부암을 치료하기 위한 글루코코르티코이드 수용체 조정제 |
CN113194931B (zh) | 2018-12-19 | 2023-11-10 | 科塞普特治疗公司 | 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂 |
WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
CN110698527B (zh) * | 2019-11-19 | 2022-08-26 | 湖南新合新生物医药有限公司 | 一种高纯度氢化可的松-17-戊酸酯的制备方法 |
CN112028956A (zh) * | 2020-09-10 | 2020-12-04 | 那路新 | 合成21-羟基-17-(1-氧代丙氧基)孕甾-4-烯-3,20-二酮的方法 |
CN114113603B (zh) * | 2021-06-30 | 2023-11-17 | 四川大学华西医院 | Cytl1作为胃癌预后标志物的应用 |
CN116135871A (zh) * | 2021-11-16 | 2023-05-19 | 石家庄迪斯凯威医药科技有限公司 | 一种具有抗耐药性的抗菌化合物 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE619180A (fr) * | 1961-06-24 | 1962-12-20 | Vismara Francesco Spa | 17-monoesters de 17 alpha, 21-dihydroxy stéroïdes et leur procédé de préparation |
DE1195748B (de) * | 1961-06-24 | 1965-07-01 | Vismara Francesco Spa | Verfahren zur Herstellung von 1'-substituierten 17alpha, 21-(1'-Alkoxy)-methylendioxysterioden |
NL6605514A (da) * | 1966-04-25 | 1967-10-26 | ||
EP0001737B1 (de) | 1977-10-26 | 1981-01-07 | Schering Aktiengesellschaft | 17-Alpha-(3-Jodbenzoyloxy)-9-Alpha-chlor-4-pregnen-3.20-dione, deren D-Homo-analoga und Verfahren zu ihrer Herstellung |
DE2748442C3 (de) | 1977-10-26 | 1981-08-27 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | 17α-(3-Jodbenzoyloxy)-9α -chlor4-pregnen-3.20-dione, Zwischenprodukte und Verfahren zu ihrer Herstellung, 9α -chlor-17α, 21-dihydroxy-1,4-pregnadien-3,20-dion und dieses enthaltende Arzneimittel |
DE3169460D1 (en) * | 1980-12-23 | 1985-04-25 | Schering Ag | 6-alpha-methyl hydrocortisone derivatives, their preparation and their utilization |
ATE8790T1 (de) | 1981-02-02 | 1984-08-15 | Schering Corporation | Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten. |
US4920216A (en) * | 1987-05-28 | 1990-04-24 | The Trustees Of Columbia In The City Of New York | Selective chlorination of steroids and other substrates directed by covalently linked pyridine derivatives acting as templates |
US5990099A (en) | 1988-10-31 | 1999-11-23 | Alcon Laboratories, Inc. | Angiostatic agents and methods and compositions for controlling ocular hypertension |
DK0464153T3 (da) | 1989-02-07 | 1995-04-24 | Upjohn Co | Dehalogenering af organiske forbindelser under anvendelse af tin eller bly |
DE4121484A1 (de) | 1991-06-26 | 1993-01-07 | Schering Ag | Verfahren zur herstellung von 6-methylensteroiden |
US6172054B1 (en) | 1995-06-15 | 2001-01-09 | Alcon Laboratories, Inc. | Combination therapy for lowering and controlling intraocular pressure |
AU3703900A (en) | 1999-02-24 | 2000-09-14 | Nitromed, Inc. | Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders |
PT1183014E (pt) | 1999-06-14 | 2003-12-31 | Cosmo Spa | Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor |
IT1314184B1 (it) | 1999-08-12 | 2002-12-06 | Nicox Sa | Composizioni farmaceutiche per la terapia di condizioni di stressossidativo |
CA2428799A1 (en) | 2000-11-16 | 2002-05-23 | Alcon Manufacturing, Ltd. | Combination therapy for lowering and controlling intraocular pressure |
ITMI20011762A1 (it) * | 2001-08-10 | 2003-02-10 | Cosmo Spa | Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione |
ITMI20051695A1 (it) * | 2005-09-14 | 2007-03-15 | Cosmo Spa | Uso di 17a-esteri c3-c10 del 9,11-deidrocortexolone cme agenti anti-gonadotropinici |
DE102006059063A1 (de) | 2005-12-24 | 2007-06-28 | Bayer Healthcare Ag | Verwendung von BAY 59-3074 zur Herstellung von Medikamenten zur Therapie von Hirntumoren sowie Kombinationen von BAY 59-3074 |
US7687484B2 (en) | 2006-05-25 | 2010-03-30 | Bodor Nicholas S | Transporter enhanced corticosteroid activity |
ITMI20071616A1 (it) * | 2007-08-03 | 2009-02-04 | Cosmo Spa | Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati. |
CN101397317A (zh) | 2007-09-27 | 2009-04-01 | 天津药业研究院有限公司 | 一种新型硝酸酯类甾体化合物 |
RU2010128239A (ru) * | 2007-12-13 | 2012-01-20 | Новартис АГ (CH) | Комбинации терапевтических средств, предназначенных для лечения рака |
US20090240049A1 (en) | 2008-03-18 | 2009-09-24 | Marco Villa | Purification of air sensitive steroids |
CA2800023A1 (en) * | 2010-06-01 | 2011-12-08 | Metanomics Health Gmbh | Means and methods for diagnosing pancreatic cancer in a subject |
US20120245552A1 (en) | 2011-03-23 | 2012-09-27 | Pop Test Cortisol Llc | Combination Therapy |
RU2506974C1 (ru) | 2012-11-06 | 2014-02-20 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ лечения первично нерезектабельного рака легкого |
JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
EP3006453A1 (en) | 2014-10-08 | 2016-04-13 | Cosmo Technologies Ltd. | 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors |
-
2014
- 2014-10-08 EP EP14188063.3A patent/EP3006453A1/en not_active Withdrawn
-
2015
- 2015-10-07 ES ES15778634T patent/ES2713699T3/es active Active
- 2015-10-07 SI SI201530614T patent/SI3204400T1/sl unknown
- 2015-10-07 HU HUE15778634A patent/HUE041503T2/hu unknown
- 2015-10-07 PL PL15778634T patent/PL3204400T3/pl unknown
- 2015-10-07 LT LTEP18198653.0T patent/LT3456330T/lt unknown
- 2015-10-07 MX MX2017004660A patent/MX366294B/es active IP Right Grant
- 2015-10-07 RU RU2017115773A patent/RU2712752C2/ru active
- 2015-10-07 CN CN202010134553.1A patent/CN111285913B/zh active Active
- 2015-10-07 US US15/517,653 patent/US10183030B2/en active Active
- 2015-10-07 RU RU2017115771A patent/RU2712950C2/ru active
- 2015-10-07 PL PL18198653T patent/PL3456330T3/pl unknown
- 2015-10-07 AU AU2015329999A patent/AU2015329999B2/en active Active
- 2015-10-07 LT LTEP15778634.4T patent/LT3204400T/lt unknown
- 2015-10-07 SI SI201531666T patent/SI3456330T1/sl unknown
- 2015-10-07 WO PCT/EP2015/073176 patent/WO2016055537A1/en active Application Filing
- 2015-10-07 CN CN201580060690.2A patent/CN107001406B/zh active Active
- 2015-10-07 US US15/517,659 patent/US10231980B2/en active Active
- 2015-10-07 KR KR1020237011743A patent/KR20230052990A/ko not_active Application Discontinuation
- 2015-10-07 IL IL272095A patent/IL272095B2/en unknown
- 2015-10-07 KR KR1020177011239A patent/KR20170063821A/ko unknown
- 2015-10-07 KR KR1020217002286A patent/KR102520411B1/ko active IP Right Grant
- 2015-10-07 ES ES18198653T patent/ES2882223T3/es active Active
- 2015-10-07 AU AU2015330003A patent/AU2015330003A1/en not_active Abandoned
- 2015-10-07 CA CA3160391A patent/CA3160391A1/en active Granted
- 2015-10-07 JP JP2017518978A patent/JP6735739B2/ja active Active
- 2015-10-07 DK DK18198653.0T patent/DK3456330T3/da active
- 2015-10-07 EP EP18198653.0A patent/EP3456330B1/en active Active
- 2015-10-07 CN CN201580060711.0A patent/CN107074905B/zh not_active Expired - Fee Related
- 2015-10-07 JP JP2017518340A patent/JP6503057B2/ja active Active
- 2015-10-07 DK DK15778634.4T patent/DK3204400T3/da active
- 2015-10-07 WO PCT/EP2015/073172 patent/WO2016055533A1/en active Application Filing
- 2015-10-07 PT PT15778634T patent/PT3204400T/pt unknown
- 2015-10-07 RS RS20210928A patent/RS62147B1/sr unknown
- 2015-10-07 CA CA2960928A patent/CA2960928C/en active Active
- 2015-10-07 MX MX2017004661A patent/MX2017004661A/es unknown
- 2015-10-07 CA CA2962746A patent/CA2962746A1/en not_active Abandoned
- 2015-10-07 ES ES15775455T patent/ES2806094T3/es active Active
- 2015-10-07 EP EP15778634.4A patent/EP3204400B1/en active Active
- 2015-10-07 TR TR2019/01422T patent/TR201901422T4/tr unknown
- 2015-10-07 BR BR112017007078A patent/BR112017007078A2/pt not_active Application Discontinuation
- 2015-10-07 HU HUE18198653A patent/HUE055143T2/hu unknown
- 2015-10-07 BR BR112017007076-6A patent/BR112017007076B1/pt active IP Right Grant
- 2015-10-07 EP EP15775455.7A patent/EP3204012B1/en active Active
- 2015-10-07 CN CN202211571443.7A patent/CN116102604A/zh active Pending
- 2015-10-07 PT PT181986530T patent/PT3456330T/pt unknown
- 2015-10-07 RS RS20190207A patent/RS58607B1/sr unknown
- 2015-10-07 KR KR1020177011114A patent/KR102248983B1/ko active IP Right Grant
- 2015-10-07 CN CN202211425819.3A patent/CN115671114A/zh active Pending
-
2017
- 2017-03-08 IL IL251028A patent/IL251028B/en active IP Right Grant
- 2017-03-23 IL IL251371A patent/IL251371A0/en unknown
- 2017-03-29 ZA ZA2017/02209A patent/ZA201702209B/en unknown
- 2017-04-07 MX MX2019008063A patent/MX2019008063A/es unknown
-
2018
- 2018-11-23 US US16/199,015 patent/US10646497B2/en active Active
-
2019
- 2019-01-17 JP JP2019006199A patent/JP7028809B2/ja active Active
- 2019-01-29 HR HRP20190194TT patent/HRP20190194T1/hr unknown
- 2019-02-12 US US16/273,575 patent/US20190175618A1/en not_active Abandoned
- 2019-04-12 ZA ZA2019/02320A patent/ZA201902320B/en unknown
-
2020
- 2020-02-27 AU AU2020201446A patent/AU2020201446B2/en active Active
- 2020-03-16 US US16/820,407 patent/US10993949B2/en active Active
- 2020-05-27 JP JP2020092411A patent/JP2020143140A/ja active Pending
- 2020-12-01 JP JP2020199555A patent/JP2021046418A/ja active Pending
-
2021
- 2021-04-06 US US17/223,776 patent/US11712443B2/en active Active
- 2021-07-22 HR HRP20211177TT patent/HRP20211177T1/hr unknown
-
2022
- 2022-12-19 US US18/068,346 patent/US11986484B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11986484B2 (en) | 17α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumors | |
CA3160391C (en) | Cortexolone 17alpha-valerate for use in the treatment of tumors | |
RU2821529C2 (ru) | 17a,21-диэфиры кортексолона для применения в лечении опухолей |